What is Cogentrx™?
Developed by Nutrisolv Corporation, Cogentrx™ is a new daily food supplement consisting of a unique combination of key vitamins, minerals and a proprietary formula (Cogentramine™) developed to support mental agility.

Who should take Cogentrx™?
Cogentrx™ is designed for high-performing business executives, successful managers and other professionals. Only with top mental agility - necessary for multi-tasking, concentration and clear, precise decision-making - are high-achievers ready for the business world and better positioned to ensure their success continues. Cogentrx™ should be taken once daily on a regular basis.

For how long should I take Cogentrx™?
ust like diets and exercises, a food supplement will not necessarily have the same impact on all people. People starting a new diet, exercise regimen, or even a new food supplement will only really begin to notice the benefits after 3-4 weeks of daily commitment.?Many individuals under pressure for top cognitive performance and in need of exceptional mental agility, who have taken Cogentrx™ daily for at least 4 weeks, have expressed their satisfaction.

Is Cogentrx™ safe? Where is it manufactured?
Cogentrx™ is a proven, safe food supplement of natural origin. In addition to the extensive research and development to obtain an optimum and safe product, our approach to product safety and manufacturing means that:

• Unlike typical food supplements, it is manufactured according to GMP (Good Manufac turing Practices) and thus to the same, strict governmental standards as for pharmaceuticals.
• From the delivery of certified raw materials to the stocking of samples from each batch, Nutrisolv runs 12 quality-assurance tests on each production run. Nutrisolv can thus guarantee that only 100% pure and safe products reach our valued customers.

How many capsules are in a pack of Cogentrx™?
A bottle of Cogentrx™ contains 120 capsules or a 4-week supply for one person.

Which side effects does Cogentrx™ have?
Cogentrx™ is a food supplement and not a drug. There were no undesired side-effects noted in any of the numerous studies involving Cogentrx™ ingredients.

Can Cogentrx™ help with ADD/ADHD?
While Cogentrx™ is not a drug, many studies of the key ingredients in Cogentrx™ have demonstrated significant benefit for individuals with ADD or ADHD.

RESEARCH
The Cogentrx™ formulation, including proprietary blend Cogentramine™, was developed by our team of world-class researchers and scientists following months of careful research. The ingredients in Cogentrx™ have been proven effective in enhancing mental agility by the world’s leading scientists. Please see below for a sampling of the research that our specialists considered in developing Cogentrx™.

1. Maes M, Smith R, Christophe A, et al. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996;38:35–46.
2. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998;48:149–55.
3. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998;43:315–9.
4. Maes M, Christophe A, Delanghe J, et al. Lowered omega 3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999;85:275–91.
5. Navarro E, Esteve M, Olivé A, et al. Abnormal fatty acid pattern in rheumatoid arthritis. A rationale for treatment with marine and botanical lipids. J Rheumatol 2000;27:298–303.
6. Belluzzi A, Brignola C, Campieri M, et al. Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn’s disease patients. Dig Dis Sci 1994;39:2589–94.
7. Burns CP, Halabi S, Clamon GH, et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 1999;5:3942–7.
8. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988;318:549–57.
9. Malasanos TH, Stacpoole PW. Biological effects of omega-3 fatty acids in diabetes mellitus. Diabetes Care 1991;14:1160–79.
10. Schectman G, Kaul S, Kassebah AH. Effect of fish oil concentrate on lipoprotein composition in NIDDM. Diabetes 1988; 37:1567–73.
11. Toft I, Bonaa KH, Ingebretsen OC, et al. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. Ann Intern Med 1995;123:911–8.
12. Luostarinen R, Wallin R, Wibell L, et al. Vitamin E supplementation counteracts the fish oil-induced increase of blood glucose in humans. Nutr Res 1995; 15:953–68.
13. Dunstan DW, Burke V, Mori TA, et al. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. Diabetes Care 1997; 20:913–21.
14. Harris WS, Zucker ML, Dujovne CA. Omega-3 fatty acids in type IV hyperlipidemia: fish oils vs methyl esters. Am J Clin Nutr 1987;45:858 [abstr].
15. Sheehan JP, Wei IW, Ulchaker M, Tserng KY. Effect of high fiber intake in fish oil-treated patients with non-insulin-dependent diabetes mellitus Am J Clin Nutr 1997; 66:1183–7.
16. Adler AJ, Holub BJ. Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men. Am J Clin Nutr 1997; 65:445–50.
17. Makoff R. Vitamin replacement therapy in renal failure patients. Miner Electrolyte Metab 1999;25:349–51 [review].
18. Heap LC, Peters TJ, Wessely S. Vitamin B status in patients with chronic fatigue syndrome. J R Soc Med 1999;92:183–5.
19. Gaby AR. Literature review & commentary. Townsend Letter for Doctors June 1990;338–9.
20. Parry G, Bredesen DE. Sensory neuropath with low-dose pyridoxine. Neurology 1985;35:1466–8.
21. Furushiro M, Suzuki S, Shishido Y, et al. Effects of oral administration of soybean lecithin transphosphatidylated phosphatidylserine on impaired learning of passive avoidance in mice. Jpn J Pharmacol 1997;75:447–50.
22. Sakai M, Yamatoya H, Kudo S. Pharmacological effects of phosphatidylserine enzymatically synthesized from soybean lecithin on brain functions in rodents. J Nutr Sci Vitaminol (Tokyo) 1996;42:47–54.
23. Blokland A, Honig W, Brouns F, et al. Cognition-enhancing properties of subchronic phosphatidylserine (PS) treatment in middle-aged rats: comparison of bovine cortex PS with egg PS and soybean PS. Nutrition 1999;15:778–83.
24. Kozikowski AP, Tückmantel W. Chemistry, Pharmacology, and Clinical Efficacy of the Chinese Nootropic Agent Huperzine A. www.huperzine.net/invent.htm, 26 June 2000.
25. Ashani Y, Peggins JO, Doctor BP. Mechanism of inhibition of cholinesterases by huperzine A. Biochem Biophys Res Commun1992;184:719–26.
26. Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 1998;60:377–86.
27. Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 1996;8:97–101.
28. Ved HS, Koenig ML, Dave JR, et al. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport 1997;8:963–8.
29. Skolnick AA. Old Chinese herbal medicine used for fever yields possible new Alzheimer’s disease therapy [news item]. JAMA1997;277:776.
30. Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer’s disease. Chung Kuo Yao Li Hsueh Pao 1995;16:391–5.
31. Zhang RW, Tang XC, Han YY, et al. Drug evaluation of huperzine A in the treatment of senile memory disorders. Chung Kuo Yao Li Hsueh Pao 1991;12:250–2 [in Chinese].
32. Wang Z, Ren G, Zhao Y, et al. A double-blind study of huperzine A and piracetam in patients with age-associated memory impairment and dementia. In: Kanba S, Richelson E (eds). Herbal Medicines for Nonpsychiatric Diseases. Tokyo: Seiwa Shoten Publishers, 1999, 39–50.
33. Sun QQ, Xu SS, Pan JL, et al. Huperizine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Acta Pharmacol Sin 1999;20:601–3.
34. Qian BC, Wang M, Zhou ZF, et al. Pharmacokinetics of tablet huperzine A in six volunteers. Chung Kuo Yao Li Hsueh Pao1995;16:396–8.
35. Collisson RJ. Siberian ginseng (Eleutherococcus senticosus). Brit J Phytother 1991;2:61–71 [review].
36. Farnsworth NR, Kinghorn AD, Soejarto DD, Waller DP. Siberian ginseng (Eleutherococcus senticosus): Current status as an adaptogen. In Economic and Medicinal Plant Research, vol 1, ed. Wagner H, Hikino HZ, Farnsworth NR. London: Academic Press, 1985, 155–215 [review].
37. Hikino H, Takahashi M, Otake K, konno C. Isolation and hypoglycemic activity of eleutherans A, B, C, D, E, F and G: glycans of Eleutherococcus senticosus roots. J Natural Prod 1986;49:293–7.
38. Wagner H, Nörr H, Winterhoff H. Plant adaptogens. Phytomed 1994;1:63–76 [review].
39. Farnsworth NR, Kinghorn AD, Soejarto DD, Waller DP. Siberian ginseng (Eleutherococcus senticosus): Current status as an adaptogen. In Economic and Medicinal Plant Research, vol 1, ed. Wagner H, Hikino HZ, Farnsworth NR. London: Academic Press, 1985, 155–215 [review].
40. Asano K, Takahashi T, Miyashita M, et al. Effect of Eleutherococcus senticosus extract on human working capacity. Planta Medica 1986;37:175–7.
41. Asano K, Takahashi T, Miyashita M, et al. Effect of Eleutherococcus senticosus extract on human working capacity. Planta Medica1986;37:175–7.
42. Kelly GS. Sports nutrition: A review of selected nutritional supplements for endurance athletes. Alt Med Rev 1997;2:282–95 [review].
43. McNaughton L. A comparison of Chinese and Russian ginseng as ergogenic aids to improve various facets of physical fitness. Int Clin Nutr Rev 1989;9:32–5.
44. Collisson RJ. Siberian ginseng (Eleutherococcus senticosus). Brit J Phytother 1991;2:61–71 [review].
45. Ben-Hur E, Fulder S. Effect of P. ginseng saponins and Eleutherococcus S. on survival of cultured mammalian cells after ionizing radiation. Am J Chin Med 1981;9:48–56.
46. Kupin VI, Polevaia EB. Stimulation of the immunological reactivity of cancer patients by eleutherococcus extract. Vopr Onkol1986;32:21–6 [in Russian].
47. Bohn B, Nebe CT, Birr C. Flow cytometric studies with Eleutherococcus senticosus extract as an immunomodulating agent.Arzneim-Forsch Drug Res 1987;37:1193–6.
48. Brown DJ. Herbal Prescriptions for Better Health. Rocklin, CA: Prima Publishing, 1996, 69–77.
49. McGuffin M, Hobbs C, Upton R, Goldberg A. American Herbal Products Association’s Botanical Safety Handbook. Boca Raton, FL: CRC Press, 1997, 45.
50. McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. Can Med Assoc J 1996;155:293–5.
51. Giovannini M, Agostoni C, Salari PC. Is carnitine essential in children? J Int Med Res 1991;19:88-102.
52. Dipalma JR. Carnitine deficiency. Am Fam Physician 1988;38:243–51.
53. Kendler BS. Carnitine: an overview of its role in preventive medicine. Prev Med 1986;15:373–90.
54. Tamamogullari N, Silig Y, Icagasioglu S, Atalay A. Carnitine deficiency in diabetes mellitus complications. J Diabetes Complications1999;13:251–3.
55. Del Favero A. Carnitine and gangliosides. Lancet 1988;2:337 [letter].
56. Kobayashi A, Masumura Y, Yamazaki N. L-carnitine treatment for congestive heart failure—experimental and clinical study. Jpn Circ J1992;56:86–94.